reports
VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganizati...
VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization CAMPBELL, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “Company”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on its Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (the “Plan”). The Bankruptcy Court approved the disclosure statement and solicitation procedures and confirmed the second amended chapter ...
VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter ...
VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date CAMPBELL, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- On November 10, 2020, VIVUS, Inc. (the “Company”), a biopharmaceutical company, filed the Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (as may be amended, modified, or supplemented from time to time, the “Plan”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). As set forth in a letter fil...
VIVUS Completes Solicitation for In-Court Reorganization Plan to Becom...
VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC CAMPBELL, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged ...
VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.
VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P. CAMPBELL, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes. Under the terms of the agreement, the Company will continue to work with IEH Biopharma on an exclusive basis in respect of any restructuring, financ...
VIVUS Reports First Quarter 2020 Financial Results
VIVUS Reports First Quarter 2020 Financial Results Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our ability to respond quickly to the COVID-19 pandemic by successfully accelerating the launch of our telemedicine and remote monitoring modules through the VIVUS Health Platform reflects our commitment to providing patients and physicians with real-world solutio...
VIVUS to Host First Quarter Business Update and Financial Results Conf...
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020 CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after the market close on Wednesday, May 6, 2020. The Company will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT the same day to review results and provide a business update. To listen via webcast, please visit , or by . To listen via phone, please use the dial in inform...
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company ...
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of approximately $170.1 million of the Company’s Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH B...
VIVUS Announces Closing of $11.55 Million Registered Direct Offering P...
VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules CAMPBELL, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per share for gross proceeds of $11.55 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. H.C. Wainwright & Co. acted as the exclusive placem...
VIVUS Announces $11.55 Million Registered Direct Offering Priced At-th...
VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules CAMPBELL, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the Company’s common stock, at a purchase price of $1.60 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April ...
VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Mod...
VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing” Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19 CAMPBELL, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the accelerated launch of the telemedicine and remote monitoring modules of the VIVUS Health Platf...
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results - Company to host conference call today at 4:30pm ET - CAMPBELL, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter and fiscal year ended December 31, 2019 and provided a business update. “Fiscal year 2019 represents our first full year of operating results as a fully integrated business and clinical team,” said John Amos, VIVUS’ Chief Executive Officer. “In 2019, our team delivered nearly $70 million of reve...
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsy...
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents -Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of patient enrollment in a Phase 4 clinical study designed to evaluate the safety and efficacy of Qsymia® (phentermine and topiramate extended-release) capsules CIV in adolescents between the a...
VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea...
VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream - VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen, has launched Qsymia (phentermine and topiramate extended-release) in the Republic of Korea. “We believe that Qsymia has significant unrealized clinical and commercial value, and the South Ko...
VIVUS to Host Fourth Quarter Business Update and Financial Results Con...
VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020 CAMPBELL, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019 after the market close on Tuesday, March 3, 2020. The company will host a conference call with accompanying presentation slides beginning at 4:30 p.m. ET / 1:30 p.m. PT the same day to review results and provide a business update. To listen via webcast, please visit , or by . To listen via...
VIVUS Receives U.S. Food and Drug Administration Approval for Improved...
VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life CAMPBELL, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE® (pancrelipase) Delayed Release Capsules that extends the shelf life to 36 months across all PANCREAZE dosages. VIVUS worked closely with Nordmark Arzneimittel GmbH & Co. KG, its manufactu...
New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Wei...
New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool -Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- CAMPBELL, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company, today announced the publication of a new study from the Toolbox Trial (NCT01922934), a real-world clinical trial conducted in urban safety-net primary care clinics offering patients a “toolbox” of cost-eff...
VIVUS to Present at Biotech Showcase on January 13, 2020
VIVUS to Present at Biotech Showcase on January 13, 2020 CAMPBELL, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will present at the Biotech Showcase™ 2020 on Monday, January 13, 2020 at 3:30 pm PT/6:30pm ET. The conference will be held at the Hilton San Francisco Union Square. An audio webcast of the presentation will be available in the events and presentations section of the Company’s investor relations website, or by . Biotech Showcase, produced by Demy-Colto...
VIVUS Adopts Stockholder Rights Plan
VIVUS Adopts Stockholder Rights Plan CAMPBELL, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in accordance with its terms on November 9, 2019. Under the new rights plan, the terms of which are substantially similar to the terms of the Company’s prior rights plan, VIVUS will issue a dividend of one right for each share of its common stock held by stockholders...
VIVUS Announces New Data Supporting the Safety and Efficacy of QsymiaÂ...
VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity -Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in obese adolescents- CAMPBELL, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the results of a pharmacokinetic (PK) and pharmacodynamic (PD) study (NCT02714062) demonstrating that Qsymia® (phent...
VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on...
VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019 CAMPBELL, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the Piper Jaffray 31st Annual Healthcare Conference at 1:10 P.M. ET on Tuesday, December 3, 2019 in New York. An audio webcast of the presentation will be available in the events and presentations section of the Company’s investor relations website, or by . About VIVUS VIVUS is a biopharmaceutic...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.